Trust & Proof: ALUNBRIG (Takeda Pharmaceutical Company) – Signal Evidence & AI Readability

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://schema.org/Patient",
    "specialty": "https://schema.org/Oncologic",
    "headline": "ALUNBRIG® (brigatinib) for ALK+ Metastatic Non-Small Cell Lung Cancer",
    "description": "Learn more about ALUNBRIG®, a treatment for adults with ALK positive NSCLC that has spread to other parts of the body. See Important Safety and Prescribing Information.",
    "url": "https://www.alunbrig.com/",
    "about": {
        "@type": "Drug",
        "name": "ALUNBRIG",
        "nonProprietaryName": "Brigatinib",
        "image": {
            "@type": "ImageObject",
            "name": "ALUNBRIG® BRIGATINIB 180mg, 90mg, 30mg TABLETS.",
            "contentUrl": "https://www.alunbrig.com/sites/default/files/2023-02/alunbrigr-brigatinib-180mg-90mg-30mg-tablets_1.png"
        },
        "description": "ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
        "pregnancyWarning": "Females and Males of Reproductive Potential: Verify pregnancy status in females of reproductive potential prior to initiating ALUNBRIG. Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in mal",
        "Warning": "IMPORTANT SAFETY INFORMATION. Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In ALTA 1L, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG. ILD/pneumonitis occurred within 8 days of initiation of ALUNBRIG in 2.9% of patients, with Grade 3 to 4 reactions occurring in 2.2% of patients. In ALTA, ILD/pneumonitis occurred in 3.7% of patie"
    },
    "potentialAction": [
        {
            "@type": "ViewAction",
            "name": "Discover ALUNBRIG",
            "url": "https://www.alunbrig.com/about-alunbrig"
        },
        {
            "@type": "ViewAction",
            "name": "If you are newly diagnoses, discover more",
            "url": "https://www.alunbrig.com/efficacy"
        },
        {
            "@type": "ViewAction",
            "name": "After treatment with Crizotinib",
            "url": "https://www.alunbrig.com/resistance"
        },
        {
            "@type": "ViewAction",
            "name": "Important Resources for You",
            "url": "https://www.alunbrig.com/resources"
        },
        {
            "@type": "ViewAction",
            "name": "Register for updates",
            "url": "https://www.alunbrig.com/sign-up"
        }
    ],
    "video": [
        {
            "@type": "VideoObject",
            "name": "Eric & Meghan's Story",
            "description": "Learn about how Eric and Meghan have navigated Eric's ALK+ mNSCLC diagnosis, their experience with ALUNBRIG, and how together they are living with lung cancer.",
            "url": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6340349834112",
            "duration": "PT12M09S",
            "embedUrl": "https://www.alunbrig.com/",
            "uploadDate": "2025-08-01",
            "interactionStatistic": {
                "@type": "InteractionCounter",
                "interactionType": {
                    "@type": "http://schema.org/WatchAction"
                }
            },
            "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/752c0c00-ca2f-4374-ad96-31455aa1c6b8/a5339da0-70f3-405c-8965-35bb925d8bb8/1280x720/match/image.jpg"
        }
    ],
    "_truncated": true,
    "_original_size": 13157
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://schema.org/Patient",
    "specialty": "https://schema.org/Oncologic",
    "sameAs": "https://en.wikipedia.org/wiki/Brigatinib",
    "headline": "Treatment for Adults With ALK+ Metastatic NSCLC",
    "description": "ALUNBRIG® (brigatinib) works as a targeted therapy to treat adults with ALK+ non-small cell lung cancer that has spread to other parts of the body. See Important Safety and Prescribing Information.",
    "url": "https://www.alunbrig.com/about-alunbrig",
    "about": {
        "@type": "Drug",
        "name": "ALUNBRIG",
        "nonProprietaryName": "Brigatinib",
        "image": {
            "@type": "ImageObject",
            "name": "ALUNBRIG® BRIGATINIB 180mg, 90mg, 30mg TABLETS.",
            "contentUrl": "https://www.alunbrig.com/sites/default/files/2023-02/alunbrigr-brigatinib-180mg-90mg-30mg-tablets_1.png"
        },
        "description": "ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
        "pregnancyWarning": "Females and Males of Reproductive Potential: Verify pregnancy status in females of reproductive potential prior to initiating ALUNBRIG. Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in mal",
        "Warning": "IMPORTANT SAFETY INFORMATION. Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In ALTA 1L, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG. ILD/pneumonitis occurred within 8 days of initiation of ALUNBRIG in 2.9% of patients, with Grade 3 to 4 reactions occurring in 2.2% of patients. In ALTA, ILD/pneumonitis occurred in 3.7% of patie"
    },
    "mainContentOfPage": [
        {
            "@type": "WebPageElement",
            "name": "What is ALUNBRIG® (brigatinib)?",
            "text": "ALUNBRIG is an FDA-approved oral prescription medication for adults with ALK-positive (ALK+) NSCLC that has spread to other parts of the body (metastatic). ALUNBRIG treatment is one tablet, taken once a day with or without food."
        },
        {
            "@type": "WebPageElement",
            "name": "Who Can Be Treated With ALUNBRIG?",
            "text": "ALUNBRIG is approved to treat adults with NSCLC: that has an abnormal ALK gene, and that has spread to other parts of the body. It is not known if ALUNBRIG is safe and effective in children."
        },
        {
            "@type": "WebPageElement",
            "name": "How Does ALUNBRIG Work?",
            "text": "ALUNBRIG, a type of targeted therapy, is a tyrosine kinase inhibitor (TKI) that can inhibit or slow the spread of non-small cell lung cancer by targeting specific proteins that are responsible for cancer cell growth.Tyrosine kinases are proteins that are part of functions like cell signaling, growth, and division. Sometimes, these proteins are too active or are found at high levels in some types of cancer cells. A TKI inhibits or blocks tyrosine kinases and may help keep cancer cells from growin"
        }
    ],
    "potentialAction": [
        {
            "@type": "ViewAction",
            "name": "Learn more about ALUNBRIG as a first treatment",
            "url": "https://www.alunbrig.com/efficacy"
        },
        {
            "@type": "ViewAction",
            "name": "Learn about ALUNBRIG after treatment another treatment",
            "url": "https://www.alunbrig.com/resistance"
        },
        {
            "@type": "ViewAction",
            "name": "See additional resources",
            "url": "https://www.alunbrig.com/resources"
        }
    ],
    "video": [
        {
            "@type": "VideoObject",
            "name": "Greg's Story",
            "description": "Learn about Greg's path to an ALK+ mNSCLC diagnosis, his treatment journey on ALUNBRIG, and how he continues to live an active lifestyle.",
            "url": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6392673725112",
            "duration": "PT12M09S",
            "embedUrl": "https://www.alunbrig.com/f9558e42-78d2-473f-bc4e-0e925577533c",
            "uploadDate": "04/08/2026",
            "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/3790bb40-41fc-4464-b3e5-f5abe8c017ed/05a36ec6-e554-4a35-8d79-8b440893351c/1280x720/match/image.jpg",
            "interactionStatistic": {
                "@type": "InteractionCounter",
                "interactionType": {
                    "@type": "http://schema.org/WatchAction"
                }
            }
        }
    ],
    "_truncated": true,
    "_original_size": 14581
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://schema.org/Patient",
    "specialty": "https://schema.org/Oncologic",
    "headline": "Benefits of ALUNBRIG® (brigatinib) as a First-Line Treatment",
    "description": "Learn how ALUNBRIG® may help as your first targeted treatment for ALK+ metastatic non-small cell lung cancer. See Important Safety and Prescribing Information.",
    "url": "https://www.alunbrig.com/efficacy",
    "about": {
        "@type": "Drug",
        "name": "ALUNBRIG",
        "nonProprietaryName": "Brigatinib",
        "image": {
            "@type": "ImageObject",
            "name": "ALUNBRIG® BRIGATINIB 180mg, 90mg, 30mg TABLETS.",
            "contentUrl": "https://www.alunbrig.com/sites/default/files/2023-02/alunbrigr-brigatinib-180mg-90mg-30mg-tablets_1.png"
        },
        "description": "ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
        "pregnancyWarning": "Females and Males of Reproductive Potential: Verify pregnancy status in females of reproductive potential prior to initiating ALUNBRIG. Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in mal",
        "Warning": "IMPORTANT SAFETY INFORMATION. Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In ALTA 1L, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG. ILD/pneumonitis occurred within 8 days of initiation of ALUNBRIG in 2.9% of patients, with Grade 3 to 4 reactions occurring in 2.2% of patients. In ALTA, ILD/pneumonitis occurred in 3.7% of patie"
    },
    "Video": [
        {
            "@type": "VideoObject",
            "name": "Katie's Story",
            "description": "Katie is a wife and mother of two. Learn about her path to an ALK+ mNSCLC diagnosis, and why ALUNBRIG was the best treatment option for her.",
            "thumbnailUrl": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/2574028764001/dca826f1-e150-4ad9-94e8-bfd568c5f844/daa37b95-477f-4bba-b3a2-bb5e17fd6f93/1280x720/match/image.jpg",
            "uploadDate": "03/01/2026",
            "duration": "PT13M05S",
            "contentUrl": "https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.html?videoId=6389065059112",
            "embedUrl": "https://www.alunbrig.com/f785673b-bdda-41f2-809d-e4bee3eba31b"
        }
    ],
    "mainContentOfPage": [
        {
            "@type": "WebPageElement",
            "name": "Patients taking ALUNBRIG lived twice as long without their disease getting worse or spreading versus those taking crizotinib",
            "text": "Study results showing that the median time to progression for patients taking ALUNBRIG® was 24 months versus 11 months for patients taking crizotinib."
        },
        {
            "@type": "WebPageElement",
            "name": "Overall Tumor Response",
            "text": "Overall, 3 out of 4 patients (74%) taking ALUNBRIG had their tumors shrink, vs 62% of patients taking crizotinib."
        },
        {
            "@type": "WebPageElement",
            "name": "ALUNBRIG Helped Shrink Tumors in the Brain",
            "text": "The Blinded Independent Review Committee also evaluated a smaller group of 41 patients with brain metastases. Overall, 14 of 18 patients (78%) achieved a response while taking ALUNBRIG vs 6 of 23 patients (26%) taking crizotinib. 3 out of every 4 patients with cancer that spread to their brain saw their tumors shrink when they were treated with ALUNBRIG. More than half of all patients (9 out of 14) who responded to ALUNBRIG maintained that response for 2 years or longer. Researchers could not es"
        },
        {
            "@type": "WebPageElement",
            "name": "People Reported a Better Quality of Life with ALUNBRIG",
            "text": "During the study, 131 people taking ALUNBRIG completed a quality of life questionnaire. Results from the questionnaire showed that people receiving ALUNBRIG went THREE TIMES LONGER without the symptoms of their cancer getting worse compared to patients treated with crizotinib. his means that the average time to symptoms getting worse was 26.7 months for patients taking ALUNBRIG compared with 8.3 months for patients taking crizotinib. The study measurement included how people functioned with the "
        }
    ],
    "potentialAction": [
        {
            "@type": "ViewAction",
            "name": "How to take ALUNBRIG",
            "url": "https://www.alunbrig.com/dosing"
        },
        {
            "@type": "ViewAction",
            "name": "See additional resources",
            "url": "https://www.alunbrig.com/resources"
        }
    ],
    "_truncated": true,
    "_original_size": 14855
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://schema.org/Patient",
    "specialty": "https://schema.org/Oncologic",
    "headline": "Using ALUNBRIG® (brigatinib) as a Second-Line Treatment",
    "description": "Learn why your healthcare provider may recommend a new line of treatment after taking crizotinib. See Important Safety and Prescribing Information.",
    "url": "https://www.alunbrig.com/resistance",
    "about": {
        "@type": "Drug",
        "name": "ALUNBRIG",
        "nonProprietaryName": "Brigatinib",
        "image": {
            "@type": "ImageObject",
            "name": "ALUNBRIG® BRIGATINIB 180mg, 90mg, 30mg TABLETS.",
            "contentUrl": "https://www.alunbrig.com/sites/default/files/2023-02/alunbrigr-brigatinib-180mg-90mg-30mg-tablets_1.png"
        },
        "description": "ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",
        "pregnancyWarning": "Females and Males of Reproductive Potential: Verify pregnancy status in females of reproductive potential prior to initiating ALUNBRIG. Advise females of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 4 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALUNBRIG and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in mal",
        "Warning": "IMPORTANT SAFETY INFORMATION. Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG. In ALTA 1L, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG. ILD/pneumonitis occurred within 8 days of initiation of ALUNBRIG in 2.9% of patients, with Grade 3 to 4 reactions occurring in 2.2% of patients. In ALTA, ILD/pneumonitis occurred in 3.7% of patie"
    },
    "mainContentOfPage": [
        {
            "@type": "WebPageElement",
            "name": "Why Did My Doctor Recommend That I Start a New Treatment?",
            "text": "Unfortunately, despite treatment-even with a targeted therapy-ALK+ non-small cell lung cancer (NSCLC) can still progress (worsen) over time. This may mean that your cancer has developed resistance to your current treatment, and it is no longer working. It's important to know that this may be expected, and you still have options. That's why your healthcare provider has recommend switching to ALUNBRIG. Your doctor may also talk to you about switching to ALUNBRIG if, while on your current treatment"
        },
        {
            "@type": "WebPageElement",
            "name": "ALUNBRIG Was Shown to Shrink Tumors After Crizotinib Treatment in Patients with ALK+ NSCLC Whose Cancer Had Spread to Other Parts of the Body",
            "text": "In a previous ALUNBRIG study, researchers followed 222 patients with ALK+ NSCLC whose cancer had spread to other parts of the body and who had taken the medicine crizotinib and whose disease had worsened. 112 patients received 90 mg of ALUNBRIG orally once daily (90-mg group). The other group of 110 patients received the recommended ALUNBRIG dosing regimen of 90 mg orally once daily for 7 days, followed by an increase to 180 mg orally once daily thereafter (90→180-mg group)."
        },
        {
            "@type": "WebPageElement",
            "name": "Additional Second-Line Study Results",
            "text": "Study Results for the Recommended Dosing Regimen (90→180-mg Group): In the same study, 18 patients receiving the recommended dosing regimen had measurable tumors that had spread to the brain. 67% of patients' brain tumors shrank: Nearly 2 out of every 3 patients saw their brain tumors shrink. None of the patients had a complete response in the brain. 67% (12 out of 18) had a partial response in the brain. Of the 12 patients who responded to treatment with ALUNBRIG: 6 patients responded for 6 mon"
        },
        {
            "@type": "WebPageElement",
            "name": "Additional Study Results for the 90-mg Group",
            "text": "26 patients with ALK+ NSCLC in the 90-mg group had measurable tumors that had spread to the brain. Overall, brain tumors shrank in 11 out of 26 (42%) patients:  out of 26 (7.7%) patients had a complete response in the brain and 9 out of 26 (35%) patients had a partial response in the brain. Of the 11 patients who responded to treatment with ALUNBRIG: 7 patients responded for 6 months or longer, and 4 patients responded for 12 months or longer"
        }
    ],
    "image": [
        {
            "@type": "ImageObject",
            "name": "Pie chart showing that 53% of patients achieved an overall response rate in the 90 mg→180 mg group.",
            "contentUrl": "https://www.alunbrig.com/sites/default/files/2022-11/fifty-three-percent-pie-chart-graphic.svg"
        },
        {
            "@type": "ImageObject",
            "name": "In a previous ALUNBRIG study, researchers followed 222 patients with ALK+ NSCLC whose cancer had spread to other parts of the body, who had taken the medicine crizotinib, and whose disease had worsened. 112 patients received 90 mg of ALUNBRIG orally once daily (90-mg group). The other group of 110 patients received the recommended ALUNBRIG dosing regimen of 90 mg orally once daily for 7 days, followed by an increase to 180 mg orally once daily thereafter (90→180-mg group).",
            "contentUrl": "https://www.alunbrig.com/sites/default/files/2024-06/3.2-study-design.svg"
        }
    ],
    "potentialAction": [
        {
            "@type": "ViewAction",
            "name": "How to take ALUNBRIG",
            "url": "https://www.alunbrig.com/dosing"
        },
        {
            "@type": "ViewAction",
            "name": "See additional resources",
            "url": "https://www.alunbrig.com/resources"
        }
    ],
    "_truncated": true,
    "_original_size": 15449
}